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Abstract 
 
Late-life depression is frequently associated with cognitive impairment. Depressive symptoms 
are often associated with or even precede a dementia syndrome. Moreover, depressive 
disorders increase the risk of persistence for mild cognitive impairment and dementia. Here, 
we present both the current state of evidence and future perspectives regarding the integration 
and value of clinical assessments, neuropsychological, neurochemical, and neuroimaging 
biomarkers for the etiological classification of the dementia versus the depression syndrome 
and for the prognosis of depression relating to dementia risk. Finally, we summarize the 
existing evidence for both pharmacotherapy and psychotherapy of depression in demented 
patients. There is an urgent need for large-scale collaborative research to elucidate the role 
and interplay of clinical and biological features in elderly individuals with depressive 
disorders who are at elevated risk for developing dementia. To overcome barriers for 
successful drug development, we propose the introduction of the precision medicine paradigm 
to this research field. 
  
Keywords: Depression, dementia, differential diagnosis, classification, prognosis, 
biomarkers, neuroimaging, pharmacotherapy, psychological intervention, precision medicine.  
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1. Introduction 
 
Dementia and depression are the most common psychiatric syndromes in older age. Although 
early identification of underlying causes and subsequent treatment are essential, the accurate 
differential diagnosis and discrimination (classification) remain clinically extremely 
challenging [1]. Late-life depression is frequently associated with cognitive impairment. In 
turn, dementia has been related to an increased risk of depressive symptoms. 
 
Dementia, a major psychopathological syndrome , is traditionally diagnosed according to very 
slowly evolving operationalized criteria manuals, including the International Statistical 
Classification of Diseases and Related Health Problems (10th revision) (ICD-10) [2] and the 
Diagnostic and Statistical Manual of Mental Disorders (5th Edition) (DSM-5), that have only 
been updated after decade long intervals [3]. Contrary to expectations, the recently published 
DSM-5 did not yet integrate any biological information (biological markers) into the 
diagnostic armamentarium The conservative primarily symptom-based, descriptive approach 
has been maintained for the neurocognitive disorders categories as well [4]. However, 
advanced expert consensus criteria have attempted classification approaches grounded on 
clinical, biological, and etiological factors. 
 
The most common underlying causes of dementia in the elderly include Alzheimer's disease 
(AD) [5], vascular dementia [6], mixed dementia, dementia with Lewy bodies [7] dementia in 
Parkinson's disease [8] and frontotemporal dementia [9] Notably, depressive symptoms have 
been reported in 30-50% of patients with AD dementia and are especially common at the 
prodromal stage [10]. Overt major depression can be diagnosed in >10% of AD patients, 
mostly during the early to moderately impaired stage [11], and in up to 50% of patients with 
vascular dementia [12–14]. Moreover, approximately 50% of patients with dementia with 
Lewy bodies show depressive symptoms [15]. 
 
Late-life depression is also generally diagnosed according to the ICD-10 [2] or DSM-5 
criteria [3]. In addition to standard clinical assessment, psychometric indexes, such as the 
Geriatric Depression Scale [16], are frequently administered in the elderly. Late-life 
depression is common in patients with chronic physical illnesses. Age- and disease-related 
changes, including arteriosclerosis, chronic inflammation, hormonal and immune 
modifications , may affect the integrity of frontostriatal circuits as well as the amygdala and 
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the hippocampus, ultimately increasing the vulnerability to depression [17]. In addition, age-
related psychosocial stressors including poor socio-economic status, disability, and social 
isolation are significant risk factors for depression [18]. Vegetative symptoms and 
impairments of executive functions, attention, information processing, psychomotor speed, 
and working memory are common. In particular, subcortical vascular changes play a major 
role in the pathophysiology of late-life depression [1] leading to the conceptualization of 
vascular depression, as defined by the results of magnetic resonance imaging (MRI) [19–22] 
The risk of suicide is approximately 2-fold higher in the elderly, especially in older males, 
compared with the general population [23]. Overall, late-life depression has distinctive 
features that allow its differentiation from depressive disorders occurring at a younger age 
[24]. 
 
2. Increased dementia risk in depression  
 
To date, most of the published studies have focused on late-life depression – i.e., depression 
in subjects aged 60 years and older – and the risk of dementia, as well as the link between 
depression and dementia; in contrast, relatively few studies have been conducted in patients 
with earlier-life depression, i.e., in subjects younger than 60 years. Since (I) depression onset 
shows a high degree of variability, (II) both young adulthood and middle age are 
characterized by a high incidence of depression, and (III) dementia is characterized by a long 
asymptomatic preclinical phase, the examination of earlier-life depression might represent an 
opportunity to examine whether depression is a risk factor for dementia many years prior to 
the advent of clinical signs. It should be acknowledged, in any case, that the association 
between late-life depression and dementia might allow for a more in-depth analysis of 
depression as part of the prodromal stage of dementia. Therefore, a careful analysis of both 
earlier-life and late-life depression is necessary to attain complementary evidence [25].  
 
The risk of developing dementia later in life increases 2-fold in presence of a positive history 
of depression at younger age. In presence of recurrent depressive disorders, a monotonic rise 
in the risk of dementia can be observed with an estimated 14% increase with each episode 
[26]. Although the available findings remain partly inconsistent, it can be assumed that late-
life depression leads to a substantially increased risk of dementia. In this setting, depression 
can be a risk factor, a prodrome, or a consequence of dementia [25]. A recent study suggested 
that chronic depression during life may be aetiologically associated with an increased risk for 
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developing dementia, particularly vascular dementia, whereas depression occurring for the 
first time in late life may reflect a prodromal stage of dementia, in particular AD [27]. 
 
Currently, various mechanisms have been proposed to explicate the association between 
depression and dementia. First, there is significant evidence indicating that vascular disease is 
the primary link between depression and dementia, which is substantiated by the “vascular 
depression hypothesis” [28,29]. This pathophysiological theory states that cerebrovascular 
disease is a risk factor, a trigger, or a perpetuating factor for depressive syndromes in the 
elderly [18,30]. In particular, vascular changes in the frontostriatal brain regions have been 
linked to both depressive symptoms and cognitive impairment [31-33]. 
 
In addition, increased cortisone levels, a biochemical alteration frequently observed in 
depressive disorders [34] can lead to worsening hippocampal atrophy associated with 
cognitive deficits [31,35]. Notably, atrophy of the hippocampus is a well-characterized brain 
alteration detected both in AD [36] and in patients with depression [37,38]. 
 
In the conceptual framework of protein misfolding disorders, the presence of accumulating 
brain amyloid beta (Aβ) plaques represents a key pathological hallmark of AD. It is well-
known that both Aβ peptides and hyperphosphorylated tau proteins accumulate significantly 
in AD brains, leading to the formation of neuritic plaques and neurofibrillary tangles, 
respectively [39,40]. Interestingly, evidence indicates that depression might lead to an 
increased disequilibrium in terms of Aβ production and/or clearance. This effect is mediated 
by the depression-related stress response and the resulting hypercortisolemia, as well as the 
direct impact on Aβ processing, probably due to alterations at the level of the serotonergic 
system [41–44]. Notably, depressed AD patients have a higher burden of Aβ plaques and 
neurofibrillary tangles in the hippocampus than AD patients without depression [45–48]. 
 
During the last decade, chronic inflammatory processes have been also implicated in both 
depression and dementia [49–51]. On the one hand, a subtle and chronic brain inflammatory 
state, inducing cellular dysbalance, the activation of microglia and reactive astrocytes, 
resulting into increased concentrations of brain cytokines detected in depression and 
dementia, may result in a reduced modulation of anti-inflammatory and immunosuppressive 
mechanisms, increased acute-phase and proinflammatory regionally spreading alterations in 
the central nervous system (CNS), and, ultimately, in a non-linear progressive fashion 
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inducing neural network dysbalance, decompensation and breakdown, cognitive deficits and 
subsequent dementia [52].  Moreover, proinflammatory cytokines overexpression are 
supposed to interfere with the serotonin metabolism, thereby decreasing both synaptic 
plasticity and hippocampal neurogenesis [42,49]. 
 
Another mechanism that may link depression with dementia is represented by decreased 
levels of circulating neurotrophic factors, mainly the brain-derived neurotrophic factor 
(BDNF). BDNF modulates neuronal structure and function and plays an important role in 
synapse development and plasticity [53]. Reduced plasma BDNF levels have been observed 
both in animal models of depression [54] as well as in patients with depression [55,56] and 
AD [57,58]. 
 
Recent data have revealed that depressed patients face an accelerated cellular aging. In 
particular, those with the most severe and chronic major depressive disorder displayed the 
shortest telomere length and participants with remitted major depressive disorders had shorter 
telomere length than controls [59]. 
 
A more comprehensive systems-based neurobiological approach – larger genetic and 
epigenetic studies, analyses of gene and biomarker expression pattern, as well as innovative 
multi-modal structural, functional and metabolic neuroimaging – is needed to shed more light 
on the pathophysiology of late-life depression. To this aim, much can be learned both 
conceptually and methodologically from recent discoveries in the field of AD [60-62]. 
 
3. Common occurrence of depression and mild cognitive impairment as a risk condition 
 
A recent large cohort study conducted in Northern Manhattan (New York, NY, USA), 
including more than 2,000 individuals aged 65 or older, has shown that late-life depression is 
associated with both an increased risk of prevalent mild cognitive impairment (MCI), an 
established risk factor for the progression and occurrence of dementia, as well as overt 
dementia itself. Depression was also associated with an increased risk of incident dementia 
but not incident MCI. Notably, individuals presenting a concomitant depressive disorder and 
MCI showed a significantly increased risk of developing dementia, in particular vascular 
dementia, compared to those with MCI without depression [63]. 
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A concomitant diagnosis of MCI has been reported in 25% to 50% of patients with late-life 
depression [64–66], compared to a 3% to 6% prevalence of MCI in community-based samples 
[11,67]. In addition, cognitive impairments emerging during a depressive episode can persist 
even after the remission of depressive symptoms [64,68]. The extent of cognitive impairment 
identified in elderly depressed patients prior to treatment seems to predict cognitive outcome 
after therapy [65,69-71]. 
 
Another recent study has demonstrated that cognitive impairment in late life depression might 
be related to greater cerebrovascular disease along with abnormalities in the immune–
inflammatory control, cell survival, intracellular signalling, protein and lipid homeostasis, and 
clotting processes. As a result, individuals with late life depression and cognitive impairment 
seem to be more susceptible to accelerated brain aging processes at the cellular and molecular 
levels [72]. 
 
4. Classification – differential diagnosis – of dementia and depression 
 
The concomitant occurrence of a depressive disorder and cognitive impairment should always 
be carefully investigated from a diagnostic viewpoint. Olin and colleagues [73,74] have 
proposed criteria to discriminate major depression and depression in AD. Accordingly, 
depression due to AD can be diagnosed when all criteria of dementia of Alzheimer type are 
fulfilled and three (or more) typical depressive symptoms have been detected during the same 
two-week period and represent a perturbation from previous physiological activity. At least 
one of the symptoms consists of either depressed mood or decreased positive affect or 
pleasure. Symptoms that are clearly due to a medical condition other than AD, or are the 
direct result of non-mood-related dementia symptoms (e.g. loss of weight due to difficulties 
with food intake) should not be included. Clinical signs are often less severe and pervasive 
than in major depression. Age of onset, rate and course of cognitive change, subjective 
memory complaints and typical sleep-wake cycle disturbances can aid in differential 
diagnosis. 
 
4.1. The emerging role of specific memory testing for the differential diagnosis 
 
AD is currently designated as a clinical entity typically characterized by a progressive 
amnestic syndrome with appearance of other cognitive, behavioural and neuropsychiatric 
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changes [75]. The episodic memory disorder, in the typical form of AD, shows a specific 
pattern which is the expression of hippocampal dysfunction and can be identified by tests 
including word list learning. This amnestic syndrome of the hippocampal type [76] is defined 
by (I) low free recall as for any brain related memory disorder; and (II) a low total recall 
performance, despite retrieval facilitation with cueing, due to hippocampal damage which 
affects the ability to store new information. Therefore, information cannot be retrieved even 
after facilitation procedures. Such a pattern demonstrates excellent specificity for AD [77]. 
 
In case of a pure depressive disorder, there is no genuine storage deficit; rather, attention 
difficulties that impair encoding or retrieval strategies can be observed [78]. Therefore, the 
differential diagnosis between AD and a pure depressive disorder can be improved by using a 
test paradigm that provides encoding specificity (with semantic cues) [79] and a retrieval 
facilitation (with the same cues), such as the free and cued selective reminding test (FCSRT) 
[80]. Regarding the memory domain, an improvement with repeated exposure and a normal 
recall with both control of encoding and retrieval cues are typically found in major 
depression, while a flat learning curve despite repeated exposure, a rapid forgetting, the 
inefficacy of cueing for recall and intrusions are typical for AD. 
 
4.2. The role of biomarkers for the differential diagnosis 
 
Whilst there are no specifically established fluid biomarkers for depression, three relevant 
biomarkers have been detected in the cerebrospinal fluid (CSF) for the key neuropathological 
alterations in AD. Actually, owing to its contiguity to the brain parenchyma and the free 
exchange with the brain extracellular space, the biochemical composition of CSF is able to 
provide information on the brain chemistry. The “core”, feasible biomarkers are: (I) total tau 
(T-tau, a marker reflecting cortical axonal degeneration), (II) phospho-tau (P-tau, a marker 
reflecting tau phosphorylation and AD-type neurofibrillary tangle pathology), both tau-related 
markers are the best indicators for disease progression, and (III) the 42 amino acid long form 
of Aβ (A1-42, a marker of senile plaque pathology) [81]. This biomarker “triad” can be used 
to examine if patients with dementia-like depressive symptoms have AD pathological 
changes. Depression per se does not result in an AD-like CSF biomarker pattern, i.e., 
increased T-tau and P-tau concentrations, and reduced levels of A1-42 [82] although 
marginally decreased CSF A1-42 concentrations have been reported [83]. A positive AD 
biomarker pattern is around 90% specific for AD neuropathology but does not exclude co-
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morbidity in AD and depression. As demonstrated by Ewers and colleagues [84] in a large-
scale multi-centric study, CSF Aβ1-42 best discriminates AD dementia from frontotemporal 
dementia, non-neurodegenerative neurological diseases and depression, but shows significant 
overlap with other non-AD forms of dementia, possibly reflecting the underlying mixed 
pathologies. The combination of the three gold-standard markers provides added diagnostic 
value; in particular, at a fixed sensitivity of 85%, the specificity was >85% [84]. 
 
Notably, several other molecular changes have been examined in CSF in relation to 
depression and dementia disorders; nevertheless, none of them has yet shown potential 
clinical utility for differential diagnosis and classification. However, depression is 
characterized by slightly increased CSF concentrations of several pro-inflammatory 
cytokines, which are most often disregarded in dementia-causing diseases [85]. Pro-
inflammatory cytokines enhance the activity of the indoleamine 2,3-dioxygenase enzyme that 
is the first rate-limiting enzyme of the tryptophan degradation pathway, the kynurenine 
pathway. Increased tryptophan degradation may induce serotonin depletion and depression, 
which is reflected by low CSF concentrations of kynurenic acid [86]. This alteration is not 
found in AD or dementia with Lewy bodies [87], which suggests that CSF kynurenic acid 
may be a promising biomarker to explore further for differential diagnosis. It is important to 
note that altered immune function is by no means specific to depression; any inflammatory 
biomarker evaluated as a potential tool to differentiate depression from dementia disorders 
has to be carefully examined in relation to diabetes, obesity, and a range of other disorders.  
 
At present, there are no established blood (plasma/serum)-based biomarkers for AD or other 
dementia-causing diseases. However, mounting evidence suggests that depression is 
associated with a pro-inflammatory cytokine response in serum. Studies have shown elevated 
serum concentrations of interleukins (ILs) such as IL-1 and IL-6, the tumour necrosis factors 
alpha (TNF-α), the C-reactive protein (CRP), and the Monocyte Chemoattractant Protein-1 
(MCP-1) in depressed patients with mixed results for IL-8 [88]. There is no study so far 
assessing the potential diagnostic and prognostic utility of this molecular pattern.  
 
4.3. The role of imaging for the differential diagnosis 
 
To some extent, CSF biomarkers listed in the previous section can also be quantified using 
positron emission tomography (PET) of the brain. The use of tracers for tau is still restricted 
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to research studies but amyloid PET is now an established diagnostic tool in many specialised 
memory clinics. Cross-sectional studies report increased amyloid depositions in cognitively 
normal depressed older individuals [89]. It seems most likely that these are individuals with 
very early stage AD which manifests with depression as first symptom. Longitudinal studies 
or studies focusing on individuals with early onset depression could provide further insights. 
A recent study did not find any significant difference in terms of brain β-amyloid deposition 
(and gray matter volume) between elderly patients with remitted major depression and 
persistent MCI compared with elderly patients with remitted major depression and normal 
cognitive function [72]. 
 
Although patients with major depression may also show an altered regional brain glucose 
metabolism as measured using [18F] Fluorodeoxyglucose – PET (FDG-PET) [90] this is far 
less consistent and pronounced and affects different regions than hypometabolism observed in 
overt clinical dementia or MCI. 
 
Besides PET, quantifying hippocampus atrophy and brain white matter lesion load are 
relevant to distinguish late-life depression from mild dementia. Although both can be assessed 
using computed tomography (CT), MRI is substantially more sensitive. Recurrent depressive 
episodes lead to hippocampus atrophy while a high number of white matter lesions is a 
common risk factor for late-onset depression and dementia, particularly of vascular origin [28, 
29]. 
 
Studies comparing the extent of hippocampus atrophy in late-onset depression and AD 
typically report substantially more pronounced atrophy in AD [91]. This result is not 
surprising given the extent of neurodegeneration observed in manifest dementia. A current 
large meta analyses indicates areas such as cingulate cortex and precuneus may serve best to 
separate AD from late-life depression [92]. The degree of hippocampal atrophy may be 
similar between subjects with MCI and those with a high number of depressive episodes; 
however, such studies are missing. 
 
On the other hand, the first appearance of depression in late life is often associated with 
increased white matter hyperintensities and clinically with lack of initiative and cognitive 
slowing. Consequently, global brain atrophy and white matter hyperintensities contribute to a 
diagnostic separation between late-life depression and healthy aging [93]. However, 
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separating patients with late-onset depression from those in the initial stages of vascular 
dementia can be difficult, particularly since both can manifest in the same individual, with 
accelerated cognitive decline and poorer response to antidepressants. 
 
5. Pharmacotherapy of depression in dementia 
 
The design and evaluation of pharmacological interventions of depression in dementia is 
challenging for several methodical reasons. The large range of published prevalence rates 
from under 5 % to nearly 50 % for major depression in AD [94,95] foreshadows the problems 
of the correct detection and diagnosis of depression in dementia. It is a well-known fact that 
cognitive decline and dementia can progressively limit language skills and self-awareness of 
depressive symptoms. The difficult differential diagnosis of apathy and depression contributes 
to the complexity. 
  
Clinical trials assessing the effects of pharmacotherapy of depression in dementia rest upon 
rating scales. The Montgomery-Asberg Depression Rating Scale (MADRS) [96] is not 
validated for demented patients [97,98]. The Hamilton Depression Rating Scale (HAM-D) 
[99] is another widely used scale that has not been validated in patients with severe dementia 
[100]. However, the Cornell Scale for Depression in Dementia (CSDD) [101] and the 
Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-
CGIC) [102] are validated in demented patients [102,103]. 
 
As reviewed recently by Leong [104] several randomized placebo-controlled interventions 
reported negative outcomes for antidepressant efficacy in dementia: with sertraline (95 mg 
daily) and mirtazapine (30 mg daily) for 13 weeks, assessed by CSDD in 326 patients [105]; 
sertraline (93 mg daily) for 24 weeks, assessed by CSDD and a modified ADCS-CGIC in 117 
patients [106]; venlafaxine (75 mg daily) for six weeks, assessed by MADRS in 31 patients 
[107] fluoxetine (maximum 40 mg daily) for six weeks, assessed by HAM-D in 41 patients 
[108]; sertraline (maximum 100 mg daily) for eight weeks, assessed by CSDD in 31 patients 
[109], imipramine (83 mg daily) for eight weeks, assessed by HAM-D in 61 patients [110]. In 
contrast, positive outcomes were reported for the following randomized placebo controlled 
trials: with sertraline (95 mg daily) for twelve weeks, assessed by CSDD and HAM-D in 44 
patients [111]; moclobemide (maximum 400 mg daily) for six weeks, assessed by HAM-D in 
511 demented patients [112]; clomipramine (maximum 100 mg daily) for six weeks, assessed 
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by HAM-D in 21 patients [113]; and citalopram (maximum 30 mg daily) for four weeks in 98 
patients [114]. 
 
In summary, well-controlled studies, systematic reviews and meta-analyses [104,105,115,116] 
have shown no reliable and convincing efficacy of antidepressants in patients with dementia 
and co-occurring depressive disorders. Even the addition of a cholinesterase inhibitor in 
depressed patients showed only a small effect on concurrent cognitive impairment and on the 
conversion rate to dementia syndrome, but with increased risk of recurrence of depression 
[117]. 
 
Given the fact that pharmacological interventions based on serotonergic and noradrenergic 
abnormalities have shown disappointing results, the discussion of novel strategies becomes 
pertinent. The role of glutamatergic signalling, especially the dysfunction of N-methyl-D-
aspartate (NMDA) receptor complex signalling, might be a promising overlap in the 
pathology of AD and major depression in late life. NMDA receptor antagonists have been 
demonstrated to feature anti-dementia as well as antidepressant potential [for review see 118]. 
These joint NMDA receptor-regulated signalling pathways in depression and dementia might 
represent a point of action in - so far treatment-resistant - depression in dementia. 
 
The sobering results of pharmacological trials also highlight the need to consider alternative 
non-pharmacological treatments; for instance, psychological and behavioural interventions. 
 
6. Psychological intervention for depression in dementia 
 
Systematic reviews provide a strong evidence base for psychotherapy as a first-line treatment 
in older depressive patients, with effect sizes comparable to those of antidepressant 
pharmacotherapy [119–122]. Moreover, the level of efficacy of psychotherapy in geriatric 
depression appears to be similar to that in younger patients [e.g. 119,123-125]. Evidence-
based recommendations have been made especially for the cognitive-behavioural therapy 
(CBT), interpersonal therapy (IPT), and problem solving therapy (PST), while the literature 
provides no profound evidence that psychodynamic therapies were less efficient compared to 
other types of psychotherapy in the treatment of geriatric depression [c.f. 121,126–128]. On 
the whole, psychotherapy in late-life could evidently use all approaches established in 
younger patients, which, however, always needs to be reviewed before application for 
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necessary modifications to accommodate age-related mental changes and relevant contextual 
characteristics in the life of elderly people [129]. 
 
A necessity for technical or procedural adaptations is particularly appropriate in older 
depressed patients with dementia, who are easily overstrained by standard psychotherapeutic 
procedures. The progressive course of disease inevitably requires permanent adaptation of 
therapeutic actions to accommodate the advancing loss of mental resources. Concrete 
modifications of psychotherapeutic procedures for elderly patients have been described in the 
literature [e.g. 130-132] and essentially comprise an increase of structure and redundancy, i.e. 
rehearsal of important issues or messages, combined with a slowing of the conversational 
flow (to accommodate slowed cognitive processing) and a flexible organization of session 
lengths, which together should preserve the patients` involvement and comprehension in the 
therapeutic process. Moreover, and partially evident from the former issues, psychotherapy in 
the elderly needs an especially active and supportive (i.e. not neutral) therapeutic stance 
combined with a limited changing intent, i.e. to adaptively shift the emphasis of therapeutic 
interventions from changing (cognition or behaviour) to insight and/or acceptance, at least in 
some domains [cf.133]. More specific modifications concern the therapeutic content and 
include a stronger interdisciplinary focus, i.e. an intensified collaboration between the 
psychotherapist on the one hand and physicians, social workers and ambulatory services on 
the other, as well as a strengthened therapeutic focus and goal-orientation such as an 
emphasized selection, prioritization, and pursuit of therapeutic goals [cf.132–134]. 
 
The necessity for major adaptations to therapeutic procedures contradicts, at least in part, the 
assumption that psychotherapy in late-life has similar outcomes, i.e. produces an equal 
amount of “positive change” as in younger patients. This claim arguably does not apply to the 
“older old” and dementia patients [cf.125,135]. Moreover, the adaptability of specific 
psychotherapies could be outpaced by a level of mental decline. Accordingly, different 
psychotherapies can be construed to have different indication areas depending on their 
individual adaptive flexibility. Concretely, modified psychodynamic therapy has been 
described to be restricted to early stages of dementia or to MCI, whereas modified 
behavioural therapy may be still practicable and effective even in severely demented patients 
[136,137]. 
 
14 
 
Despite the evident limitations and barriers, there is a constantly growing evidence-base for 
psychotherapy in dementia patients, data which evidently provide a valuable alternative or 
complementary treatment option to the pharmacotherapy of neuropsychiatric and particularly 
depressive symptoms. More specifically, a series of studies show that the adapted application 
of standard psychotherapies like CBT, PST, and IPT (compared to usual community or 
residential care) has a moderate effect on the level of depression in dementia and, hence, the 
potential to significantly improve the patients’ psychological well-being [138,139; for review, 
see 135,140]. 
 
Of note, these results compare quite favourably with the limited effects of 
psychopharmacological interventions on depression in dementia patients, who in addition are 
more susceptible to adverse side effects and interaction effects than younger patients [cf.141]. 
As a restriction, however, participants of such studies mostly have mild dementia so that it 
remains unclear as to whether similar positive effects of nonpharmacological interventions 
can be achieved in more severe forms, too. Problem Adaptation Therapy (PATH) [142] is a 
relative novel psychotherapeutic intervention specifically designed for the treatment of 
depression in dementia. This therapy, which can be applied from mild cognitive deficits to 
moderate dementia, specifically aims to strengthen the patient’s emotional regulation and for 
this purpose integrates a problem solving approach with environmental adaptation, 
compensatory strategies, and caregiver participation. In a recent efficacy evaluation study 
[143] PATH has been compared to supportive therapy for cognitively impaired patients and, 
thereby, has been shown to be superior in the reduction of depressive symptoms. The authors 
conclude that PATH may provide a valuable relief to a large group of dementia patients. 
 
Other psychological interventions which have been evaluated in dementia patients are not 
specifically or uniquely aimed at the reduction of depressive symptoms, but follow more 
general or nonspecific goals like e.g. to increase social interaction, to stimulate memory, 
and/or to stabilize the sense of identity. These therapies have been developed specifically for 
the treatment of dementia patients, so-called “dementia-specific therapies”, and, therefore, can 
be generally applied without adaptation, even in advanced disease stages. Even though 
dementia-specific therapies are not specifically aimed at the reduction of depressive 
symptoms, they still may improve the patients’ mood and reduce the emotional stress related 
to dementia. Reminiscence therapy and Validation therapy, for instance, are “emotion-
oriented” psychological interventions, which can be applied to treatment for MCI and all 
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stages of dementia. Reminiscence therapy [144] consists of different techniques to stimulate 
memories of personal history and thereby to reactivate life experiences, particularly positive 
ones, and their related mood states. Techniques to make these memories more meaningful are 
e.g. asking deepening questions, which suggest the importance of the life event or the 
allocation of historical materials like vintage photographs, documents or auditory records. 
Validation therapy [e.g.145] was originated and further developed by gerontologist Naomi 
Feil. This therapy focuses on the comprehension of emotional messages, which are assumed 
to lie behind the partly confused speech and behaviour of the dementia patient. According to 
the therapy rationale, dementia patients actively retreat to an inner reality, which is based on 
feelings rather than intellect, because they cannot tolerate their present reality. Based on this 
assumption, validation therapists prioritize the emotional content over the person’s orientation 
to the present, so to speak, and accordingly validate (i.e. mirror and confirm) the 
communicative efforts of the patients rather to correct them in their confused expressions. 
This procedure is expected to reduce negative affect and consequent behavioural disturbances. 
 
Unfortunately, dementia-specific therapies still have a rather weak or inconclusive evidence 
base [e.g.146–148], while, however, a lack of evidence can and should not be interpreted as 
proof of inefficacy. Validation therapy and Reminiscence therapy, among other dementia-
specific psychotherapies, are clinically relevant and an inherent part of the dementia care 
practice [e.g.146]. 
 
7. Conclusions and future directions 
 
Both depression and cognitive decline impose a significant burden on public health. It has 
been shown that depressive syndromes have distinct features in the elderly. Close monitoring 
of cognitive disorders in elderly people showing depressive symptoms is of paramount 
importance and the presence of dementia should be excluded through extensive 
neuropsychological investigations. At present, although core, feasible AD neuroimaging 
modalities and neurochemical CSF biomarkers show evolving evidence, they have not yet 
been generalized world-wide and implemented in guidelines for clinical practice and are not 
routinely utilized in patients with late-life depression for differential diagnosis/classification 
and progression/prognosis. 
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Whereas psychological interventions have shown promising beneficial results, the clinical 
utility of approved antidepressant pharmacotherapies in patients with dementia and depression 
remains questionable. Actually, the understanding of the biological mechanisms underlying 
both dementia and depressive disorders as well as their genetically-biologically determined 
endophenotypes deserve further scrutiny and may pave the way for the development of novel 
diagnostic strategies and primary therapeutic targets for both dementia and depression. In this 
scenario, future studies should investigate clinical and biological features that may predict the 
development of persistent cognitive impairment in both earlier-life and late-life depression. 
 
Preventive strategies against cognitive decline should take into account the patients’ affective 
vulnerability. Moreover, much research effort should be devoted to the understanding of the 
neurobiology of depression with concomitant cognitive decline, with special reference to the 
involvement of networks and neurotransmitter systems that may differ from those affected in 
depression without cognitive decline.  
 
It appears that there is an urgent need for large-scale collaborative research to shed more light 
on the role of clinical, neuroimaging, neuropsychological, genetic, neurochemical, and 
environmental characteristics of patients with late-life depression. In addition, studies on their 
significance for the prediction of cognitive decline and dementia development need to be 
performed. 
 
In general, depressive syndromes present a highly heterogeneous spectrum of clinical 
phenotypes and are characterized by a still largely unclarified, intricate genetics and biology 
reflecting a partly overlapping variety of underlying aetiologies. In addition, pathological 
findings in different brain areas show a high degree of interindividual variability. In order to 
take these factors into adequate account, further research is needed into the phenomenology 
and neurobiology of depression in different ages of life, in patients with neurodegenerative 
and vascular diseases as well as in those showing pathologically mixed forms. In order to 
achieve this goal, a large amount of demographic, psychopathological, genetic, biomarker, 
and imaging data should be gathered in a standardized fashion. All these variables need to be 
analysed both cross-sectionally and longitudinally. These results would be invaluable for 
refining research hypotheses and designing further studies aimed at developing novel 
interventional strategies in preclinical models and, subsequently, in clinical cohorts. 
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However, despite decade-long research in the fields of neurobiology and neuropsychology of 
depression and dementia translated clinical progress seems still very limited. A more 
progressive conceptual paradigm shift inspired by other more advanced fields in healthcare – 
such as oncology – should transfertilize research in neuroscience providing better solutions 
also for these complex neuropsychiatric disorders. As a consequence of the prevailing 
conceptual traditionalism and stagnation in Neuropsychiatry, both dementia and depression 
are still considered, since approximately a century, as clinically descriptive categorical entities 
and continue to be classified according to descriptive operationalized criteria catalogues. The 
assumption that a few drug classes will fit all genetic and biological heterogeneous clinically 
defined target populations (syndromes and “disease” entities) is treacherous and unlikely to 
lead to success. 
 
The precision medicine paradigm [149,150], adopted from oncology (e.g. in patients with 
adenocarcinomas and lung cancer) may offer a way out. To this aim, we need to accept the 
notion that patients can indeed be stratified by complex genetic, epigenetic, and genomic 
patterns, by subsequent molecular and cellular pathways that can be tracked and that serve as 
targets for intervention. These biological conditions emerge (often) long before first clinical 
symptoms arise, which suggests the exploration of “silent” preclinical stages before 
symptoms and syndromes emerge as late stage signs of underlying disease. Biological 
markers reflecting specific biochemistry and mechanisms of action as well as 
pathophysiology need to systematically be discovered and validated. In this regard, the 
systems biology paradigm [61,151] - representing an integrated investigation of interacting 
biomolecules within cells and organisms and allowing comprehensive exploratory biomarker 
studies – offers the adequate toolset for supporting precision medicine. 
 
Actually, the evolving hypothesis-free exploratory paradigm of systems biology, also referred 
to as integrative biology or network biology [152,153] is an integrative interdisciplinary 
strategy exploiting advances in multimodal high-throughput technological platforms enabling 
the investigation of networks of biological pathways where elevated amounts of 
structurally/functionally different molecules are simultaneously explored over time at a 
system level (i.e., at the level of cells, tissues, organs, apparatuses, or even whole organism). 
This approach requires the comprehensive enumeration and quantification of biological 
processes, followed by efficient data analysis and integration, to allow the generation of 
hypotheses that need to be validated at a system level [151]. 
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Technologies utilized in systems biology are the high-throughput screening methods typical 
of the omic sciences, namely: genomics/epigenomics, transcriptomics, 
proteomics/peptidomics, and metabolomics/lipidomics. Omics-based data provide a 
comprehensive picture on complex systems at molecular level, which can be used to 
systematically elucidate molecular mechanisms of living organisms. Thus, omics sciences can 
inform a more definite prediction of the risk of developing the disease, its progression, the 
severity of symptoms, personalized to a specific individual [61,62]. This information is 
necessary to tailor precisely both prevention strategies and therapeutic approaches to that 
subject as well as to provide suitable decisions regarding lifestyle and preventative treatments. 
 
In order to develop targeted therapeutic strategies in the field of depression, depression in 
dementia and dementia in depression, it is mandatory to integrate cutting-edge multi-modal 
biomarker technologies and transfertilization from more matured translational research fields, 
such as the previously mentioned area of oncology. These progresses will lead to a radical 
paradigm shift: from the traditional reductionistic “one-drug-fits-all” approach to the concept 
of precision medicine enabling the identification of patients who would likely benefit the most 
from a treatment and suffer the least side effects [154]. For instance, the genetic makeup most 
likely associated with the molecular mechanisms of action of a drug can be revealed, thus 
increasing the probability of a patient’s response to the therapy. This helps to identify better 
matches for existing and novel drugs, with the aim of ensuring that the “right drug” is 
delivered to the “right patient” at the “right time”, with the highest possible success at lowest 
risk [155]. 
 
A precision medicine and, consequently, more comprehensive systems-based neurobiological 
approach – requiring larger genetic/genomic (e.g. whole genome and exome sequencing) and 
epigenomic studies, analyses of gene and biomarker expression patterns, as well as with 
innovative multi-modal structural, functional and metabolic neuroimaging – is therefore 
needed to gain more insights into late-life depression. To this aim, much can be learned both 
conceptually and methodologically from recent discoveries in the field of AD [61,62]. 
 
In summary, the aim of precision medicine is specifically targeting the molecular and clinical 
heterogeneity by identifying an individual’s comprehensive and specific pattern of risk 
factors, by defining the precise underlying molecular pathophysiologic processes, and, lastly, 
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by aiming to administer a preventive or therapeutic intervention specifically “customized”, 
i.e. adapted, to the identified molecular pattern of risk and disease processes 
 
Finally, in the context of the precision medicine paradigm, the putative application of a 
multimodal model that may integrate into the pathophysiology of depression both imaging 
and biomarker data, which are well established for dementia, can ultimately reduce the burden 
of late-life depression on healthcare systems. Similarly, the burden would be decreased on the 
patients and their families, as a result of most appropriate prevention and clinical 
management. The availability of risk information assessed and specified for individuals with 
depression would facilitate clinicians’ informed decision-making on cognitive outcomes, 
basically targeting a modifiable risk factor (i.e., depressed mood) for dementia. 
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